Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Intervention group :After calculating the amount of calories needed by each person using the Meflin formula, each person For 12 weeks, receiving the co-administration of DASH and inte
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years Having evidence of non-alcoholic fatty liver in fibroscan (CAP score>260) Not having a history of alcohol consumption or alcohol consumption less than 10 grams per day in women and less than 20 grams per day in men. Not taking drugs that affect blood lipids, metformin, vitamin E and ursodeoxycholic acid (UDCA) and hepatotoxic drugs such as phenytoin, amoxifen and lithium. Not having chronic and acute liver diseases (hepatitis B, C, etc.), biliary disease, known autoimmune diseases, cancer and hereditary disorders affecting the liver (iron, copper storage disease) No history of weight loss surgery, weight loss program in the last 3 months Non-adherence to special diets such as vegetarianism No history of uncontrolled thyroid disease Willingness to participate in the studuy Not having uncontrolled celiac disease, diabetes, cardiovascular disease, lung disease and kidney disease
Exclusion criteria
Exclusion criteria: History of weight loss surgery and weight loss program during the last 3 months Failure to accept study conditions Taking medicine or supplements that can affect the results Following special diets and vegetarianism during the last 3 months Pregnancy or breastfeeding in women or Using birth control pills
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of steatosis and liver fibrosis. Timepoint: At the beginning and 3 months after the start of the study. Method of measurement: Fibroscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid profile. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Insulin sensitivity index. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: math formula.;Insulin resistance index. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: math formula.;Insulin concentration. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Anthropometric indices. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: Tape measure, scale and mathematical formula.;Blood pressure. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: Sphygmomanometer.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample.;Liver enzymes alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase. Timepoint: At the beginning of the study and at the end of the study (after 3 months). Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzita Hekmatdoost
Shahid Beheshti University of Medical Sciences
Outcome results
None listed